Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2025 08:30 ET | Source: Clene Inc.

Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
December 03, 2025 08:00 ET | Source: Clene Inc.

Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival,...
December 02, 2025 17:39 ET | Source: Clene Inc.

Clene to Provide CNM-Au8® ALS Program Update

SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...
November 20, 2025 08:00 ET | Source: Clene Inc.

Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference

SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
November 13, 2025 08:00 ET | Source: Clene Inc.

Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights

As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly The FDA advised Clene to request a Type C meeting to...
October 20, 2025 08:30 ET | Source: Clene Inc.

Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
October 15, 2025 08:30 ET | Source: Clene Inc.

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
September 25, 2025 08:00 ET | Source: Clene Inc.

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and...
September 04, 2025 08:30 ET | Source: Clene Inc.

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease

Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize...
September 02, 2025 08:00 ET | Source: Clene Inc.

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...